Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Soligenix Mid-Year Report Strong for Biodefense Efforts

    By Global Biodefense StaffAugust 12, 2015
    Biodefense and Health Security Industry News
    Share
    Facebook LinkedIn Reddit Email

    Soligenix, Inc., a late-stage biopharmaceutical company developing products in the areas of biodefense, inflammation, and oncology, today announced highlights and financial results for the first half of 2015.

    During this timeframe, the company initiated a development agreement with Emergent BioSolutions Inc. to implement a commercially viable, scalable production process for the RiVax, a vaccine candidate being developed for protection against ricin exposure.

    Under the agreement, Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.

    Also on the biodefense front, Soligenix this year expanded their ThermoVax technology platform via a collaboration with the University of Hawaiʻi at Manoa and Hawaii Biotech, Inc. to develop a heat stable Ebola vaccine.

    In addition, Soligenix entered a collaboration with the National Organization for Rare Disorders (NORD) and the Cutaneous Lymphoma Foundation (CLF) to support recruitment into the SGX301 pivotal Phase 3 cutaneous T-cell lymphoma (CTCL) clinical study set to begin in the second half of 2015.

    “Following the end of the second quarter, we increased our access to capital by entering into a $10 million equity purchase agreement with accredited investors,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “This funding, to be used at our sole discretion, has the potential to fund ongoing development initiatives for our late-stage product candidates, including the Phase 3 CTCL clinical study. Our cash position for the second quarter ended June 30, 2015 was $4.0 million versus $5.0 million at March 31, 2015.”

    In June 2015, Soligenix also announced the publication of data by the University of Colorado demonstrating a heat stable vaccine formulation of a Human Papillomavirus (HPV) vaccine. Soligenix has not licensed or acquired any rights to this vaccine and related patent applications, but the study demonstrated the successful conversion of a commercial virus-like particle based vaccine requiring cold-chain storage to a subunit, alum adjuvanted, vaccine which is stable at ambient temperatures.

    Source: Soligenix press release, adapted. Rivax and ThermoVax are trademarked, protected terms by Soligenix, Inc.

    Ricin Strategic National Stockpile Thermostability Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleState Policies Influence Vaccination, Outbreak Rates
    Next Article African Continent Marks 1 Year Polio-Free

    Related Stories

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.